Self-reported medication in community-dwelling older adults in Germany: results from the Berlin Initiative Study
Tóm tắt
Older adults have the highest drug utilization due to multimorbidity. Although the number of people over age 70 is expected to double within the next decades, population-based data on their medication patterns are scarce especially in combination with polypharmacy and potentially inappropriate medication (PIM). Our objective was to analyse the frequency of polypharmacy, pattern of prescription (PD) and over-the-counter (OTC) drug usage, and PIMs according to age and gender in a population-based cohort of very old adults in Germany. Cross-sectional baseline data of the Berlin Initiative Study, a prospective cohort study of community-dwelling adults aged ≥70 years with a standardized interview including demographics, lifestyle variables, co-morbidities, and medication assessment were analysed. Medication data were coded using the Anatomical Therapeutic Chemical (ATC) classification. Age- and sex-standardized descriptive analysis of polypharmacy (≥5 drugs, PD and OTC vs. PD only and regular and on demand drugs vs regular only), medication frequency and distribution, including PIMs, was performed by age (
Tài liệu tham khảo
Wallace E, Salisbury C, Guthrie B, Lewis C, Fahey T, Smith SM. Managing patients with multimorbidity in primary care. BMJ. 2015;350:h176.
Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65(9):989–95.
Elmståhl S, Linder H. Polypharmacy and Inappropriate Drug Use among Older People—a Systematic Review. Healthy Aging Clin Care Elderly. 2013;5(3642-HACCE-Polypharmacy-and-Inappropriate-Drug-Use-among-Older-People—a-Systema.pdf):1–8.
Nobili A, Franchi C, Pasina L, Tettamanti M, Baviera M, Monesi L, et al. Drug utilization and polypharmacy in an Italian elderly population: the EPIFARM-elderly project. Pharmacoepidemiol Drug Saf. 2011;20(5):488–96.
Franchi C, Tettamanti M, Pasina L, Djignefa CD, Fortino I, Bortolotti A, et al. Changes in drug prescribing to Italian community-dwelling elderly people: the EPIFARM-elderly project 2000-2010. Eur J Clin Pharmacol. 2014;70(4):437–43.
Morin L, Johnell K, Laroche ML, Fastbom J, Wastesson JW. The epidemiology of polypharmacy in older adults: register-based prospective cohort study. Clin Epidemiol. 2018;10:289–98.
Caughey GE, Roughead EE, Pratt N, Shakib S, Vitry AI, Gilbert AL. Increased risk of hip fracture in the elderly associated with prochlorperazine: is a prescribing cascade contributing? Pharmacoepidemiol Drug Saf. 2010;19(9):977–82.
Haider SI, Johnell K, Thorslund M, Fastbom J. Trends in polypharmacy and potential drug-drug interactions across educational groups in elderly patients in Sweden for the period 1992–2002. Int J Clin Pharmacol Ther. 2007;45(12):643–53.
Milton JC, Hill-Smith I, Jackson SH. Prescribing for older people. BMJ. 2008;336(7644):606–9.
Lai SW, Liao KF, Liao CC, Muo CH, Liu CS, Sung FC. Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. Medicine (Baltimore). 2010;89(5):295–9.
Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–9.
Venturini CD, Engroff P, Ely LS, Zago LF, Schroeter G, Gomes I, et al. Gender differences, polypharmacy, and potential pharmacological interactions in the elderly. Clinics (Sao Paulo). 2011;66(11):1867–72.
Bradley MC, Fahey T, Cahir C, Bennett K, O'Reilly D, Parsons C, et al. Potentially inappropriate prescribing and cost outcomes for older people: a cross-sectional study using the Northern Ireland enhanced prescribing database. Eur J Clin Pharmacol. 2012;68(10):1425–33.
Kojima G, Bell C, Tamura B, Inaba M, Lubimir K, Blanchette PL, et al. Reducing cost by reducing polypharmacy: the polypharmacy outcomes project. J Am Med Directors Assoc. 2012;13(9):818 e11–5.
Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230.
Payne RA. The epidemiology of polypharmacy. Clin Med (Lond). 2016;16(5):465–9.
Eickhoff C, Hammerlein A, Griese N, Schulz M. Nature and frequency of drug-related problems in self-medication (over-the-counter drugs) in daily community pharmacy practice in Germany. Pharmacoepidemiol Drug Saf. 2012;21(3):254–60.
Corsonello A, Pranno L, Garasto S, Fabietti P, Bustacchini S, Lattanzio F. Potentially inappropriate medication in elderly hospitalized patients. Drugs Aging. 2009;26(Suppl 1):31–9.
Tommelein E, Mehuys E, Petrovic M, Somers A, Colin P, Boussery K. Potentially inappropriate prescribing in community-dwelling older people across Europe: a systematic literature review. Eur J Clin Pharmacol. 2015;71(12):1415–27.
Schubert I, Kupper-Nybelen J, Ihle P, Thurmann P. Prescribing potentially inappropriate medication (PIM) in Germany's elderly as indicated by the PRISCUS list. An analysis based on regional claims data. Pharmacoepidemiol Drug Saf. 2013;22(7):719–27.
Weng MC, Tsai CF, Sheu KL, Lee YT, Lee HC, Tzeng SL, et al. The impact of number of drugs prescribed on the risk of potentially inappropriate medication among outpatient older adults with chronic diseases. QJM. 2013;106(11):1009–15.
Older people in Germany and the EU. Federal Statistical Office; 2016.
Peters E, Pritzkuleit R, Beske F, Katalinic A. Demographic change and disease rates: a projection until 2050. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2010;53(5):417–26.
Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet. 2009;374(9696):1196–208.
Knopf H, Melchert HU. Bundes-Gesundheitssurvey: Arzneimittelgebrauch. Beiträge zur Gesundheitsberichterstattung des Bundes. Berlin: Robert Koch-Institut; 2003.
Knopf H, Grams D. Medication use of adults in Germany: results of the German health interview and examination survey for adults (DEGS1). Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2013;56(5–6):868–77.
Amann U, Schmedt N, Garbe E. Prescribing of potentially inappropriate medications for the elderly: an analysis based on the PRISCUS list. Dtsch Arztebl Int. 2012;109(5):69–75.
Ebert N, Jakob O, Gaedeke J, van der Giet M, Kuhlmann MK, Martus P, et al. Prevalence of reduced kidney function and albuminuria in older adults: the Berlin initiative study. Nephrol Dial Transplant. 2017;32(6):997–1005.
Schaeffner ES, van der Giet M, Gaedeke J, Tolle M, Ebert N, Kuhlmann MK, et al. The Berlin initiative study: the methodology of exploring kidney function in the elderly by combining a longitudinal and cross-sectional approach. Eur J Epidemiol. 2010;25(3):203–10.
WHO. Guidelines for ATC classification and DDD assignment 2013. Oslo: Collaborating Centre for Drug Statistics Methodology. ATC/DDD index; 2012.
Medicinal Products Act: Federal Ministry of Justice and Consumer Protection; 2015 [Available from: http://www.gesetze-im-internet.de/englisch_amg/index.html.
Holt S, Schmiedl S, Thurmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int. 2010;107(31–32):543–51.
Brauns H, Scherer S, Steinmann S. The CASMIN educational classification in international comparative research. In: Hoffmeyer-Zlotnik JHPW C, editor. Advances in cross-national comparison. New York: Kluwer; 2003. p. 221–44.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.
Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–51.
Schaeffner ES, Ebert N, Delanaye P, Frei U, Gaedeke J, Jakob O, et al. Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med. 2012;157(7):471–81.
Stavropoulou C. Non-adherence to medication and doctor-patient relationship: evidence from a European survey. Patient Educ Couns. 2011;83(1):7–13.
Neves SJ, Marques AP, Leal MC, Diniz Ada S, Medeiros TS, Arruda IK. Epidemiology of medication use among the elderly in an urban area of northeastern Brazil. Rev Saude Publica. 2013;47(4):759–67 discussion 68.
Payne RA, Avery AJ, Duerden M, Saunders CL, Simpson CR, Abel GA. Prevalence of polypharmacy in a Scottish primary care population. Eur J Clin Pharmacol. 2014;70(5):575–81.
Chen YF, Dewey ME, Avery AJ. Analysis Group of the MSTMRCCF, ageing S. self-reported medication use for older people in England and Wales. J Clin Pharm Ther. 2001;26(2):129–40.
Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract. 2005;17(4):123–32.
Junius-Walker U, Theile G, Hummers-Pradier E. Prevalence and predictors of polypharmacy among older primary care patients in Germany. Fam Pract. 2007;24(1):14–9.
Schmiedl S, Rottenkolber M, Hasford J, Rottenkolber D, Farker K, Drewelow B, et al. Self-medication with over-the-counter and prescribed drugs causing adverse-drug-reaction-related hospital admissions: results of a prospective, long-term multi-Centre study. Drug Saf. 2014;37(4):225–35.
Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65.
Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867–78.
Qato DM, Wilder J, Schumm LP, Gillet V, Alexander GC. Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern Med. 2016;176(4):473–82.
WHO. Noncommunicable diseases [Available from: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases.
Moen J, Antonov K, Larsson CA, Lindblad U, Nilsson JL, Rastam L, et al. Factors associated with multiple medication use in different age groups. Ann Pharmacother. 2009;43(12):1978–85.
Silwer L, Lundborg CS. Patterns of drug use during a 15 year period: data from a Swedish county, 1988--2002. Pharmacoepidemiol Drug Saf. 2005;14(11):813–20.
Hanlon JT, Fillenbaum GG, Ruby CM, Gray S, Bohannon A. Epidemiology of over-the-counter drug use in community dwelling elderly: United States perspective. Drugs Aging. 2001;18(2):123–31.
Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287(3):337–44.
Nahin RL, Pecha M, Welmerink DB, Sink K, DeKosky ST, Fitzpatrick AL, et al. Concomitant use of prescription drugs and dietary supplements in ambulatory elderly people. J Am Geriatr Soc. 2009;57(7):1197–205.
McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379(16):1509–18.
Zheng SL, Roddick AJ. Association of Aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA. 2019;321(3):277–87.
McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018;379(16):1519–28.
McNeil JJ, Woods RL, Nelson MR, Reid CM, Kirpach B, Wolfe R, et al. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med. 2018;379(16):1499–508.
Guallar E, Stranges S, Mulrow C, Appel LJ, Miller ER 3rd. Enough is enough: stop wasting money on vitamin and mineral supplements. Ann Intern Med. 2013;159(12):850–1.
Rochon PA. Drug prescribing for older adults 2018 [Available from: https://www.uptodate.com/contents/drug-prescribing-for-older-adults.
Stock S, Redaelli M, Simic D, Siegel M, Henschel F. Risk factors for the prescription of potentially inappropriate medication (PIM) in the elderly : an analysis of sickness fund routine claims data from Germany. Wien Klin Wochenschr. 2014;126(19–20):604–12.
Riens B, Mangiapane S. Aerztliche Verordnungen von Wirkstoffen der PRISCUS-Liste – Relevanz und regionale Unterschiede. Zentralinstitut für die kassenaerztliche Versorgung in Deutschland; 2012.